NRX Pharmaceuticals, Inc. Convertible Notes Payable, Noncurrent
NRX Pharmaceuticals, Inc. (NRXP) had Convertible Notes Payable, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ConvertibleLongTermNotesPayable · last filed 2026-03-23
- 2025-12-31: Convertible Notes Payable, Noncurrent $0.00.
- 2025-09-30: Convertible Notes Payable, Noncurrent $0.00.
- 2025-06-30: Convertible Notes Payable, Noncurrent $0.00.
- 2025-03-31: Convertible Notes Payable, Noncurrent $0.00.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-18 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 |
| 2024-12-31 | $5.01M 10-K · filed 2026-03-23 |
| 2024-09-30 | $2.98M 10-Q · filed 2024-11-14 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |